ClinicalTrials.gg
Sign In

Leukemia, Prolymphocytic clinical trials

The registry lists 172 studies for Leukemia, Prolymphocytic across more than 10 countries. 5 are recruiting or about to start. 9 of them are mainly about Leukemia, Prolymphocytic (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-28. Counting its narrower condition Leukemia, Prolymphocytic, T-Cell too: 198 studies, 13 open.

Get an email when these change. Save the Leukemia, Prolymphocytic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
112
Terminated
28
Withdrawn
11
Status unknown
9
Active, not recruiting
7
Recruiting
5

Phase

Phase 2
70
Phase 1
67
Phase 3
16
Early Phase 1
1

Where

United States
144
Italy
8
Germany
8
Switzerland
6
France
5
Canada
4

Who runs them

Fred Hutchinson Cancer Center (16) · National Cancer Institute (NCI) (16) · Masonic Cancer Center, University of Minnesota (12) · M.D. Anderson Cancer Center (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · Alliance for Clinical Trials in Oncology (5) · Case Comprehensive Cancer Center (5) · Chinese PLA General Hospital (4)

What is being tested here

Drugs under test in Leukemia, Prolymphocytic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Fludarabine2129
Cyclophosphamide1121
Mycophenolic Acid1115
Allopurinol103
Treosulfan101
Fludarabine phosphate0120
Rituximab0012
Tacrolimus0010
Busulfan019
Antilymphocyte Serum018

Drug classes tested here Antimetabolites 2 open · Alkylating agents 2 open · Calcineurin inhibitors 17 · Tyrosine kinase inhibitors (TKIs) 8 · Proteasome inhibitors 3

Coming up

0phase 3 studies under way
4studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 4

Who these studies take

Of the 5 Leukemia, Prolymphocytic studies recruiting now, 2 (40%) set no upper age limit and 2 (40%) stop at 75 or younger. 3 (60%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.

Recruiting studies that take each age, of 5
AgeWomenMen
103 (60%)3 (60%)
184 (80%)4 (80%)
304 (80%)4 (80%)
404 (80%)4 (80%)
504 (80%)4 (80%)
654 (80%)4 (80%)
754 (80%)4 (80%)
853 (60%)3 (60%)

Across all 172 studies, recruiting or not: 32% stop at 75 or younger and 14% at 65; 33% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Prolymphocytic studies take

Of 20 phase 2 interventional studies under Leukemia, Prolymphocytic, half reached primary completion within 95 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 164 mo39–82 · 10 studies——
Phase 295 mo64–159 · 20 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 172. Browse all 172 → or search them.